E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Healthy volunteers (The effect of flurosemide, together with an infusion of hypertone saline, on the kidneys, using biomarkers) |
Raske forsøgspersoner (ved hjælp af biomarkører ledes efter effekten af flurosemid, under infusion af hyperton natriumklorid, på nyrerne) |
|
E.1.1.1 | Medical condition in easily understood language |
Healthy volunteers (The effect of the diuretic flurosemide, together with an infusion of high concentration saline, on the kidneys, using biomarkers) |
Raske forsøgspersoner (ved hjælp af biomarkører ledes efter effekten af det vanddrivende stof flurosemid, under infusion af saltvand med høj koncentration, på nyrerne) |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Physiological processes [G07] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | SOC |
E.1.2 | Classification code | 10022891 |
E.1.2 | Term | Investigations |
E.1.2 | System Organ Class | 10022891 - Investigations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To investigate the effect of chloride together with flurosemide on the kidneys in a randomized, single-blind, placebo-controlled, cross-over study in healthy subjects, by measuring biomarkers, kidney function and vasoactive hormones. |
At undersøge klorids sammen med flurosemids effekt på nyrerne i et randomiseret, enkeltblindet, placebokontrolleret, overkrydset forsøg hos raske forsøgspersoner, ved måling af biomarkører, nyrefukntion og vasoaktive hormoner. |
|
E.2.2 | Secondary objectives of the trial | |
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Men and Women • age 18-40 • BMI 18,5-30,0 kg/m2 Fertile women most use safe contraceptives through the trail period, defined as intrauterine devices, abstinens and hormonal contraceptives (birth control pills, contraceptives implants, contraceptives injektion, contraceptives patch, vaginal ring). Excepted are postmenopausal women with no menstruation in at least 12 month before inclusion, surgical sterilization or women with sterilized regular partner. |
• Mænd og kvinder • Alder 18-40 år • BMI 18,5-30,0 kg/m2 Fertile kvinder skal anvende sikker antikonception gennem hele forsøgsperioden, defineret som spiral, afholdenhed eller hormonel antikonception (p-piller, implantat, transdermal depotplaster, vaginalring eller depotinjektion). Undtaget herfra er postmenopausale kvinder med udebleven menstruation i mindst 12 måneder før inklusion, kirurgisk steriliserede og kvinder med steriliseret fast partner. |
|
E.4 | Principal exclusion criteria |
• Tobacco smoking (Non-smokers in more than 3 months can be included) • Medicine- or drug abuse • Alcohol abuse >14 units for women >21 units for men • Medical treatment (over the counter medication will evaluated whether or not it is grounds for exclusion) within 2 weeks before the trail period starts except contraception. • Pregnancy or nursing • Neoplastic disorders • Significant clinical signs of heart-, lung-, liver-, kidney-, endocrine- or brain disorders • Clinically significant abnormal findings in screening blood samples, urine sample or ECG • Office blood pressure over 140/90 mmHg • Donation of blood within 1 month of the first day of investigation. • Allergy against compounds in investigational medicine
|
• Tobaksrygning (rygestop på over 3 måneder kan inkluderes) • Medicin- eller stofmisbrug • Alkoholoverforbrug, dvs. >14 genstande/uge for kvinder og >21 genstande/uge for mænd • I medicinsk behandling (inkl. Håndkøbsmedicin (paracetamol eller andre præparater som ved lægelig vurdering findes ikke at interferer med projektet godtages)) inden for de sidste to uger før undersøgelsesdagene, fraset antikonception • Graviditet eller amning • Neoplasi • Anamnestiske eller kliniske tegn på betydende hjerte-, lunge-, lever-, nyre-, stofskiftesygdomme eller neurologiske lidelser • Klinisk betydende afvigelser ved screeningsblodprøver, urinstix eller EKG • Konsultationsblodtryk >140/90 mmHg • Bloddonation inden for den seneste måned inden første undersøgelsesdag • Allergi overfor et af indholdsstofferne i forsøgsmedicinen
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Urinary neutrophil gelatinase-associated lipocalin concentration |
urin neutrophil gelatinase-associated lipocalin koncentration |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
When all subjects have completed and the blood and urine samples have been analyzed. |
Når alle forsøgspersoner er afsluttet og blod- samt urinprøver analyseret. |
|
E.5.2 | Secondary end point(s) |
Biomakers: u-KIM, u-FABP, TIMP, IGFBP7 Vasoactive hormones: PRC, p-Ang-II, p-AVP, p-Aldo Transport channels: u-AQP2, u-EnaC, u-NCC, u-NK2CC Kidney physiology: 51Cr-EDTA-clearance, FENa CH2O, TCO2, p-Cl, u-Cl, Hemodynamic: Puls, central and brachial blood pressure
|
Biomakør: u-KIM, u-FABP, TIMP, IGFBP7 Vasoaktive hormoner: PRC, p-Ang-II, p-AVP, p-Aldo Transportkanaler: u-AQP2, u-EnaC, u-NCC, u-NK2CC Nyrefysiologi: 51Cr-EDTA-clearance, FENa CH2O, TCO2, p-Cl, u-Cl, Hæmodynamik: Puls, central og brakial blodtryk
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
When all subjects have completed and the blood and urine samples have been analyzed. |
Når alle forsøgspersoner er afsluttet og blod- samt urinprøver analyseret. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |